Here we will review the preclinical and clinical evidence demonstrating SFK involvement in BCR-ABL signaling, the transforming activity of BCR-ABL, progression of CML and Ph+ ALL, and imatinib resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.